Medigene AG (HAM:MDG1)
Germany · Delayed Price · Currency is EUR | Market Cap | 256.07K -85.2% |
| Revenue (ttm) | 7.45M -17.5% |
| Net Income | -15.93M |
| EPS | -1.26 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,292 |
| Open | 0.0050 |
| Previous Close | 0.0050 |
| Day's Range | 0.0050 - 0.0060 |
| 52-Week Range | 0.0050 - 0.0188 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Medigene AG
Medigene AG is in the process of liquidation of its remaining assets. Previously, the company was engaged in the development of T-cell therapies for the treatment of cancer. Medigene AG was founded in 1994 and is headquartered in Munich, Germany. [Read more]
Financial Performance
In 2023, Medigene AG's revenue was 6.03 million, a decrease of -80.69% compared to the previous year's 31.25 million. Losses were -16.18 million, 94.2% more than in 2022.
Financial StatementsNews
Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Technology in the U.S.
Planegg/Martinsried, February 19, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) , an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapi...
Medigene AG announces closing of its first SEPA tranche
Planegg/Martinsried, February 3, 2025. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)...
Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers
Planegg/Martinsried, December 9, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)...
Medigene AG Transcript: Status Update
Capital will be refocused on off-the-shelf TCR-guided therapies, with MDG3010 as the lead program and autologous programs paused except for MDG1015, which is delayed pending financing. A 40% workforce reduction and cost measures align with the new strategy, while partnerships and financial options are actively pursued.
Medigene AG Slides: Status Update
Medigene AG has posted slides in relation to its latest quarterly earnings report, which was published on November 27, 2024.
Medigene AG Quarterly report: Q3 2024
Medigene AG has published its Q3 2024 quarterly earnings report on October 24, 2024.
Medigene AG Slides: R&D Event
Medigene AG has posted slides in relation to its latest quarterly earnings report, which was published on October 10, 2024.
Medigene AG Expands Protection of its KRAS Library with Filing of New Patent Application Supporting MDG2021
Planegg/Martinsried, September 25, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (T...
Medigene AG Secures Two Additional Patents for Technologies in Its End-to-End Platform
Planegg/Martinsried, August 29, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-...
Medigene AG implements announced 2:1 share capital reduction and consolidation of the shares effective August 29, 2024
Number of shares issued decreases from 29,475,189 to 14,737,594 due consolidation of the shares at a ratio of 2:1 Consolidation of shares to take place on August 29, 2024 Planegg/Martinsried, August 2...
Medigene AG Earnings Call Transcript: H1 2024
Revenue grew 45% year-over-year to EUR 4.5 million, with an improved EBITDA and extended cash runway into July 2025. Lead TCR-T program MDG1015 is on track for clinical trial initiation by year-end, supported by new partnerships and a successful capital raise.
Medigene AG Quarterly report: H1 2024
Medigene AG has published its H1 2024 quarterly earnings report on August 14, 2024.
Medigene AG Slides: H1 2024
Medigene AG has posted slides in relation to its H1 2024 quarterly earnings report, which was published on August 14, 2024.
Medigene AG Reports Half-Year 2024 Financial Results and Provides Corporate Update
Significant corporate and scientific progress in the first half of 2024 Advancement of lead program MDG1015 with IND filing on track for 3Q 2024 and CTA filing for 4Q 2024 New additions to End-to-End ...
Medigene AG to Report Half-Year 2024 Financial Results on August 14, 2024
Planegg/Martinsried, August 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-g...
Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China
Planegg/Martinsried, July 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunothe...
Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office
Planegg/Martinsried, May 28, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunoth...
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
Cash runway extended into July 2025 from previously April 2025 Capital raise strengthens Medigene's financial position Lead program, MDG1015, on track for IND filing in 3Q 2024 and CTA filing in 4Q 20...
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunother...
Medigene AG Quarterly report: Q1 2024
Medigene AG has published its Q1 2024 quarterly earnings report on April 26, 2024.
Medigene AG reports Financial Results and Business Update for Q1 2024
Planegg/Martinsried, April 26, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunot...
Medigene AG Secures European Patent for its iM-TCR Technology
Planegg/Martinsried, April 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Medigene AG Earnings Call Transcript: H2 2023
Medigene AG Quarterly report: H2 2023
Medigene AG has published its H2 2023 quarterly earnings report on March 28, 2024.
Medigene AG Slides: H2 2023
Medigene AG has posted slides in relation to its H2 2023 quarterly earnings report, which was published on March 28, 2024.